Zacks: Analysts Expect Cardiff Oncology, Inc. (NASDAQ:CRDF) Will Post Quarterly Sales of $80,000.00

Wall Street analysts expect Cardiff Oncology, Inc. (NASDAQ:CRDF – Get Rating) to report $80,000.00 in sales for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Cardiff Oncology’s earnings, with the lowest sales estimate coming in at $50,000.00 and the highest estimate coming in at $100,000.00. Cardiff Oncology posted sales of $70,000.00 in the same quarter last year, which would indicate a positive year over year growth rate of 14.3%. The company is scheduled to issue its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that Cardiff Oncology will report full-year sales of $300,000.00 for the current year, with estimates ranging from $200,000.00 to $400,000.00. For the next fiscal year, analysts anticipate that the business will post sales of $200,000.00. Zacks’ sales averages are an average based on a survey of sell-side research firms that that provide coverage for Cardiff Oncology.

Cardiff Oncology (NASDAQ:CRDF – Get Rating) last announced its quarterly earnings results on Thursday, February 24th. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.06). Cardiff Oncology had a negative return on equity of 21.05% and a negative net margin of 7,880.50%.

Several brokerages recently weighed in on CRDF. William Blair started coverage on shares of Cardiff Oncology in a research report on Wednesday, January 5th. They issued an “outperform” rating on the stock. Zacks Investment Research cut shares of Cardiff Oncology from a “hold” rating to a “sell” rating in a research report on Wednesday, March 2nd. Maxim Group cut their price objective on shares of Cardiff Oncology from $25.00 to $14.00 in a research report on Monday, January 24th. Finally, HC Wainwright reiterated a “buy” rating and set a $25.00 price objective on shares of Cardiff Oncology in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, Cardiff Oncology currently has an average rating of “Buy” and an average price target of $16.25.

A number of hedge funds have recently bought and sold shares of the stock. Nisa Investment Advisors LLC bought a new stake in shares of Cardiff Oncology during the third quarter valued at approximately $47,000. Citigroup Inc. lifted its holdings in shares of Cardiff Oncology by 105.1% in the 4th quarter. Citigroup Inc. now owns 10,574 shares of the company’s stock worth $64,000 after buying an additional 5,419 shares during the period. Metropolitan Life Insurance Co NY purchased a new stake in shares of Cardiff Oncology in the 3rd quarter worth $74,000. Invesco Ltd. purchased a new stake in shares of Cardiff Oncology in the 2nd quarter worth $87,000. Finally, GSA Capital Partners LLP purchased a new stake in shares of Cardiff Oncology in the 4th quarter worth $93,000. 59.52% of the stock is currently owned by institutional investors.

CRDF traded down $0.05 during trading hours on Tuesday, hitting $2.08. The company’s stock had a trading volume of 446,717 shares, compared to its average volume of 798,212. The business’s 50-day moving average price is $2.65 and its 200-day moving average price is $4.70. Cardiff Oncology has a 12 month low of $2.06 and a 12 month high of $10.24. The stock has a market cap of $90.08 million, a price-to-earnings ratio of -2.93 and a beta of 1.84.

Cardiff Oncology Company Profile (Get Rating)

Cardiff Oncology, Inc, a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.

Recommended Stories